These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21040725)

  • 1. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.
    Veerapu NS; Raghuraman S; Liang TJ; Heller T; Rehermann B
    Gastroenterology; 2011 Feb; 140(2):676-685.e1. PubMed ID: 21040725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.
    Hedenstierna M; Weiland O; Brass A; Bankwitz D; Behrendt P; Uhnoo I; Aleman S; Cardell K; Fryden A; Norkrans G; Eilard A; Glaumann H; Pietschmann T; Sällberg M; Brenndörfer ED
    Aliment Pharmacol Ther; 2015 Mar; 41(6):532-43. PubMed ID: 25627143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
    Lehmann M; Meyer MF; Monazahian M; Tillmann HL; Manns MP; Wedemeyer H
    J Med Virol; 2004 Jul; 73(3):387-91. PubMed ID: 15170633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong hepatitis C virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children.
    Hashem M; El-Karaksy H; Shata MT; Sobhy M; Helmy H; El-Naghi S; Galal G; Ali ZZ; Esmat G; Abdelwahab SF; Strickland GT; El-Kamary SS
    J Infect Dis; 2011 Mar; 203(6):854-61. PubMed ID: 21257736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
    Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P
    Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
    J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
    Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
    Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome.
    Löhr HF; Gerken G; Roth M; Weyer S; Schlaak JF; Meyer zum Büschenfelde KH
    J Hepatol; 1998 Oct; 29(4):524-32. PubMed ID: 9824260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trace amounts of sporadically reappearing HCV RNA can cause infection.
    Veerapu NS; Park SH; Tully DC; Allen TM; Rehermann B
    J Clin Invest; 2014 Aug; 124(8):3469-78. PubMed ID: 25003189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.
    Rohrbach J; Robinson N; Harcourt G; Hammond E; Gaudieri S; Gorgievski M; Telenti A; Keiser O; Günthard HF; Hirschel B; Hoffmann M; Bernasconi E; Battegay M; Furrer H; Klenerman P; Rauch A;
    Gut; 2010 Sep; 59(9):1252-8. PubMed ID: 20660698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
    Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
    Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Late spontaneous elimination of HCV-RNA from mononuclear cells derived from peripheral blood in patients with chronic hepatitis C].
    Majda-Stanisławska E; Sidorkiewicz M; Jóźwiak B; Pietrzak A; Brzezińska-Błaszczyk E
    Przegl Epidemiol; 2006; 60(1):79-85. PubMed ID: 16758743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Radkowski M; Gallegos-Orozco JF; Jablonska J; Colby TV; Walewska-Zielecka B; Kubicka J; Wilkinson J; Adair D; Rakela J; Laskus T
    Hepatology; 2005 Jan; 41(1):106-14. PubMed ID: 15619235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.
    Khedr MA; E Behairy B; Hussein ME; Marei AM; Nage SA; Zakaria HM
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1170-4. PubMed ID: 26148246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
    Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M
    J Clin Virol; 2010 Mar; 47(3):258-62. PubMed ID: 20116330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
    Rockstroh JK; Feld JJ; Chevaliez S; Cheng K; Wedemeyer H; Sarrazin C; Maasoumy B; Herman C; Hackett J; Cohen DE; Dawson GJ; Cloherty G; Pawlotsky JM
    J Virol Methods; 2017 Jul; 245():14-18. PubMed ID: 28359920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.